Atlas Trials

Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

Clinical trial NCT03298412 · TERMINATED

Trial details

NCT number
NCT03298412
Sponsor
Amgen
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
High-risk Diffuse Large B-cell Lymphoma
Start date
2018-05-23
Primary completion
2019-09-30
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.